000868117 001__ 868117
000868117 005__ 20210130004112.0
000868117 0247_ $$2doi$$a10.1080/14737175.2020.1704256
000868117 0247_ $$2ISSN$$a1473-7175
000868117 0247_ $$2ISSN$$a1744-8360
000868117 0247_ $$2Handle$$a2128/23998
000868117 0247_ $$2pmid$$apmid:31829748
000868117 0247_ $$2WOS$$aWOS:000503631900001
000868117 037__ $$aFZJ-2019-06704
000868117 082__ $$a610
000868117 1001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b0$$eCorresponding author$$ufzj
000868117 245__ $$aAdvantages and limitations of amino acid PET for tracking therapy response in glioma patients
000868117 260__ $$aAbingdon$$bTaylor & Francis Group$$c2020
000868117 3367_ $$2DRIVER$$aarticle
000868117 3367_ $$2DataCite$$aOutput Types/Journal article
000868117 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1579705540_19971
000868117 3367_ $$2BibTeX$$aARTICLE
000868117 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000868117 3367_ $$00$$2EndNote$$aJournal Article
000868117 520__ $$aIntroduction: Today, magnetic resonance imaging (MRI) is the standard method for monitoring patients with brain tumors. The ability of conventional MRI in differentiating neoplastic tissue from nonspecific, treatment-related changes after surgery, radio-, chemo- or immunotherapy, however, remains limited. Therefore, advanced MRI sequences and positron emission tomography (PET) are increasingly being considered to improve decision-making.Areas covered: PET using radiolabeled amino acids has evolved into an important diagnostic tool to overcome some of the shortcomings of conventional MRI. In view of the rapidly developing novel treatment strategies, a reliable statement on the response to therapy is becoming increasingly important. This article gives an overview of the current results of PET with radiolabelled amino acids in therapy monitoring of standard therapy as well as various innovative approaches in the treatment of patients with cerebral gliomas.Expert opinion: Amino acid PET has proven to be helpful in therapy monitoring of gliomas, the costs are low in relation to the costs of therapy and the clinical benefit, and a widespread clinical use is highly desirable.
000868117 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000868117 588__ $$aDataset connected to CrossRef
000868117 7001_ $$0P:(DE-Juel1)132315$$aHeinzel, Alexander$$b1$$ufzj
000868117 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b2$$ufzj
000868117 7001_ $$0P:(DE-Juel1)132318$$aMottaghy, Felix M.$$b3$$ufzj
000868117 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b4$$ufzj
000868117 773__ $$0PERI:(DE-600)2090856-8$$a10.1080/14737175.2020.1704256$$gp. 14737175.2020.1704256$$n2$$p137-146$$tExpert review of neurotherapeutics$$v20$$x1744-8360$$y2020
000868117 8564_ $$uhttps://juser.fz-juelich.de/record/868117/files/Langen_Post%20Print_2019_Expert%20Review%20of%20Neurotherapeutics_Advantages%20and%20limitations%20of%20amino%20acid%20PET%20for%20tracking%20therapy%20response.pdf$$yPublished on 2019-12-18. Available in OpenAccess from 2020-12-18.
000868117 8564_ $$uhttps://juser.fz-juelich.de/record/868117/files/Langen_Post%20Print_2019_Expert%20Review%20of%20Neurotherapeutics_Advantages%20and%20limitations%20of%20amino%20acid%20PET%20for%20tracking%20therapy%20response.pdf?subformat=pdfa$$xpdfa$$yPublished on 2019-12-18. Available in OpenAccess from 2020-12-18.
000868117 909CO $$ooai:juser.fz-juelich.de:868117$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000868117 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b0$$kFZJ
000868117 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132315$$aForschungszentrum Jülich$$b1$$kFZJ
000868117 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b2$$kFZJ
000868117 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132318$$aForschungszentrum Jülich$$b3$$kFZJ
000868117 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b4$$kFZJ
000868117 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000868117 9141_ $$y2020
000868117 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000868117 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000868117 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEXPERT REV NEUROTHER : 2017
000868117 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000868117 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000868117 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000868117 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000868117 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000868117 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000868117 920__ $$lyes
000868117 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000868117 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000868117 980__ $$ajournal
000868117 980__ $$aVDB
000868117 980__ $$aUNRESTRICTED
000868117 980__ $$aI:(DE-Juel1)INM-3-20090406
000868117 980__ $$aI:(DE-Juel1)INM-4-20090406
000868117 9801_ $$aFullTexts